Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) Operating Expenses (2016 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Operating Expenses for 15 consecutive years, with $594.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Expenses rose 22.42% year-over-year to $594.6 million, compared with a TTM value of $2.2 billion through Dec 2025, up 25.58%, and an annual FY2025 reading of $2.2 billion, up 25.58% over the prior year.
  • Operating Expenses was $594.6 million for Q4 2025 at Neurocrine Biosciences, up from $555.9 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $594.6 million in Q4 2025 and bottomed at $205.1 million in Q1 2021.
  • Average Operating Expenses over 4 years is $422.7 million, with a median of $438.3 million recorded in 2024.
  • Peak annual rise in Operating Expenses hit 33.1% in 2024, while the deepest fall reached 22.18% in 2024.
  • Year by year, Operating Expenses stood at $247.3 million in 2021, then skyrocketed by 47.55% to $364.9 million in 2023, then soared by 33.1% to $485.7 million in 2024, then increased by 22.42% to $594.6 million in 2025.
  • Business Quant data shows Operating Expenses for NBIX at $594.6 million in Q4 2025, $555.9 million in Q3 2025, and $541.9 million in Q2 2025.